Medical network on December 21 - trapped in medicare payments, highly anticipated new cholesterol-lowering drugs PCSK9 inhibitors in the United States market performance is far less than expected. From the situation, hard to parcel out the PCSK9 inhibitors in a few years in China, even if this kind of drugs in the domestic market, also difficult to advantage in the short term, the cholesterol is still the statin drugs market all over the world.
Statin cholesterol domination
According to the CFDA institute of medicine economic south punctuation information company "China city public hospital chemical medicine terminal monitoring analysis system" (HDM), according to data from 2015 samples of the key cities for the domestic hospital adjust blood lipid drug overall market has reached 2.402 billion yuan, compared with the same period last year growth of 6.58%.
With the improvement of people raises the blood fat drug awareness, domestic statins market shows a tendency of rapid growth. Relevant data show that in 2015 the domestic adjust blood lipid drug overall market has reached 21.812 billion yuan, compared with the same period last year growth of 8.08%, which statin terminal retail market occupy 80% of the overall market.
According to HDM system according to the latest figures, the first half of 2016 samples of the key cities for the domestic hospital adjust blood lipid drug overall market has reached 1.265 billion yuan, the TOP five varieties was followed by atorvastatin, rui shu laval statin, horse statin, pravastatin and simvastatin, accounting for 87.16% of the total market, shows a high concentration.
Atorvastatin is ahead
According to HDM system, according to data from 2015 samples of the key cities for the domestic hospital drug atorvastatin overall market has reached 1.18 billion yuan, compared to the same period last year growth of 4.31%.
Competitive brands include: American Pfizer's lipitor, occupied 77.02% market share; Beijing jia Lin pharmaceutical co., LTD. The first copy medicine "ALe" accounted for 18.63%. Through the market cultivation, "ALe" is the domestic market of statins in 3rd varieties. In addition, topfond pharmaceutical "preferred" account for 3.68%, other company sales of atorvastatin accounted for 0.67%.
Atorvastatin compound preparation research pipeline vitality infinite. At this stage has entered clinical atorvastatin compound preparations are: atorvastatin + amlodipine piece, atorvastatin + plug horse cloth, atorvastatin + sinistral amlodipine piece. New drug release technology, compound preparations will be during the period of "much starker choices-and graver consequences-in" bright spot.
Shu cut statin slowing growth
On April 10, 2007, astrazeneca's rui shu laval statin approved listed in China, commodity called "can".
As rob of awareness of imitation, domestic enterprises also quick layout. Have many local brands to enter the market, the main dosage forms are tablets, capsules and tablets. Are respectively the purport of southern shandong Bert ", "Beijing's" new zhejiang Beijing, nanjing zhengda "completed" the weather is fine and the first sound of east yuan "march". After 2013, zhejiang sea are pharmaceutical, hainan general sanyo, nolato, group the pharmaceutical industry, such as shandong lang's four has approved production shu cut statins.
According to HDM system, according to data from 2015 samples of the key cities for the domestic hospital, shu statin cut overall market has reached 583 million yuan, up 4.48% over the same period last year, compared statin's overall market by 15.43%. In the sample hospitals, astrazeneca can account for 73.82% of southern shandong Bert "rui purport" occupy 11.69%, "Beijing's" new zhejiang Beijing accounted for 7.6%, nanjing zhengda shine "completed" accounted for 5.56%, other companies account for 1.33%. The drug market entered the stage of slow growth, competition among enterprises.
Cut statin was a late bloomer
Horse cutting statin and three were successfully developed by Japan period company, registered in Japan in November 1999, listed by FDA approval in 2008, the goods is called "force". Domestic horse cutting statin by China resources first copy, double crane pharmaceutical goods, called "cool". At present, the biochemical medicine co LTD., zhejiang and jiangsu wanbang Beijing new pharmaceutical, shandong qi are pharmaceutical cutting statins have been cleared by the CFDA, the horse into the sample hospital market. On April 29, 2016, shiyao group of novartis pharmaceutical licensed horses cut statin drug ingredients listed.
According to HDM system, according to data from 2015 samples of the key cities for the domestic hospital horse cutting statin market has reached 97.36 million yuan, year-on-year growth of 110.96% a year. Statin listed trees, after starting period, has entered the growth period, belongs to breed was a late bloomer.
Pravastatin enduring
Pravastatin is the result of microbial products, by the Japanese daiichi pharmaceutical co., study success and listed in Japan in 1989 took the lead, commodity called "beauty park town". The bristol-myers squibb permission, cooperation to jointly develop sales in the global market. In 1991 America's bristol-myers squibb pravastatin getting listed on the FDA approved in the United States, goods is called "oprah". And the drug in Europe multinational used for clinical purposes, enduring the statin market so far.
Pravastatin is introduced into the Chinese market in 1995, approved by state food and drug registration. Pravastatin is a unique mechanism of cholesterol-lowering drugs, in the process of human metabolism by bile and kidney dual channel discharge, which earned his place in the call fat difference market.
As the original drug chemical patent expires, it has as a generic drugs into the market. Domestic pravastatin API by Shanghai day wei biopharmaceuticals, guangdong sapphire pharmaceutical and the new method shows beijiang pharmaceutical shares listed. Pravastatin preparations by the sea is Pfizer, Shanghai modern pharmacy, north China pharmaceutical and pharmaceutical method.
According to HDM system, according to data from 2015 samples of the key cities for the domestic hospital pravastatin market has reached 96.83 million yuan, year-on-year growth of 8.26% a year, one of the daiichi sankyo "beauty park town" accounted for 81.76%, the sea is Pfizer's "altruism" accounted for 10.96%, bristol-myers squibb "rosuvastatin" account for 2.99% of the north China pharmaceutical "blessing he ning", guangdong and Shanghai modern "PuHuiZhi" method pravastatin capsule combined accounted for 4.29% of the market.
|
